Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 6,958

Document Document Title
WO/2007/123942A2
The present invention relates to methods for synthesizing compounds of formula (I) or pharmaceutically acceptable salts thereof: Formula (I) wherein each of R1, R2, R3, R4, x, m, n, and Ar are as defined, and described in classes and sub...  
WO/2007/115968A3
Provided is a process for the preparation of 2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-((R)-3-oxocyclope ntyl)-N-pyrazin-2-ylpropionamide of formula (I) and its isopropanol solvate as a glucokinase activator which increases insulin secr...  
WO/2007/115968A2
Provided is a process for the preparation of 2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-((R)-3-oxocyclope ntyl)-N-pyrazin-2-ylpropionamide of formula (I) and its isopropanol solvate as a glucokinase activator which increases insulin secr...  
WO/2007/114213A1
[PROBLEMS] To provide a compound capable of inhibiting the production of a prostaglandin or leukotriene. [MEANS FOR SOLVING PROBLEMS] Disclosed is a compound represented by the general formula (I) or a salt thereof: (I) wherein (a) repre...  
WO/2007/107276A2
The present invention relates to a process for preparing C7 intermediates and their use in the preparation of pyrrole derivatives of a class that is effective at inhibiting the biosynthesis of cholesterol in humans, and more particularly...  
WO/2007/107276A3
The present invention relates to a process for preparing C7 intermediates and their use in the preparation of pyrrole derivatives of a class that is effective at inhibiting the biosynthesis of cholesterol in humans, and more particularly...  
WO/2007/099553A3
The present invention relates to novel 1,3-dioxane carboxylic acids of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods fo...  
WO/2007/099553A2
The present invention relates to novel 1,3-dioxane carboxylic acids of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods fo...  
WO2007057703B1
Process for the preparation of statins, in particular atorvastatin via intermediates of Formula (1) and a process for the preparation of said intermediates.  
WO/2007/096261A3
The present invention is concerned with a novel process for the preparation of compounds of formula (I), wherein R1 and R2 are as defined in the description and claims. The compounds of formula (I) are pharmaceutically active substances.  
WO/2007/096261A2
The present invention is concerned with a novel process for the preparation of compounds of formula (I), wherein R1 and R2 are as defined in the description and claims. The compounds of formula (I) are pharmaceutically active substances.  
WO/2007/083640A1
[PROBLEMS] To provide a drug which has a selective β3 receptor activating effect and is useful in preventing or treating increased urinary frequency and urinary incontinence. [MEANS FOR SOLVING PROBLEMS] It is disclosed that 6-[2-(R)-[(...  
WO/2007/074776A1
The invention aims at providing a simple and easy method by which many kinds of organic chemicals (contaminants) can be efficiently decomposed in a short time and separated and recovered as insoluble matter. Water or soil contaminated wi...  
WO/2007/069773A1
The present invention provides a novel modulator of the TRPV1-receptor function, comprising a compound of the formula; wherein ring A is an optionally substituted carbocycle or heterocycle, ring B is an optionally substituted benzene rin...  
WO/2007/069777A3
Conventional fungicidal compositions have had practical problems such that either a preventive effect or a curative effect is inadequate, the residual effect tends to be inadequate, or the controlling effect against plant diseases tends ...  
WO/2007/069777A2
Conventional fungicidal compositions have had practical problems such that either a preventive effect or a curative effect is inadequate, the residual effect tends to be inadequate, or the controlling effect against plant diseases tends ...  
WO/2007/068330A1
The present invention relates to 2-adamantylurea derivatives of formula (I) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and the use of such compounds for the treatment and prevention of m...  
WO/2007/063925A1
Disclosed is a novel and excellent therapeutic or prophylactic agent for nociceptive pain, neuropathic pain, cancer pain, headache, bladder dysfunction or the like, which relies on a preventive activity on capsaicin receptor VR1 activati...  
WO/2007/057703A2
Process for the preparation of statins, in particular atorvastatin via intermediates of Formula (1) and a process for the preparation of said intermediates.  
WO/2007/057703A3
Process for the preparation of statins, in particular atorvastatin via intermediates of Formula (1) and a process for the preparation of said intermediates.  
WO/2007/051762A1
The invention relates to a process for producing trioxane and at least one comonomer for producing (co)polymers on a trioxane basis, in which, in a first step, formaldehyde and at least one comonomer starting material are reacted in aque...  
WO/2007/052831A1
A compound represented by the formula (I): wherein Ar represents a group represented by the formula: (wherein Y represents methylene or an oxygen atom, R1 represents aminosulfonyl, C1-6 alkylaminosulfonyl, C1-6 alkylcarbonylamino or C1-6...  
WO2006081276A8
Compounds of the formula where the variables have the meaning defined in the specification have analgesic and or immunostimulant effect in mammals.  
WO/2007/048717A1
Methodologies for the alpha-monohalogenation of acid sensitive ketones, especially cyclic, acid-sensitive, ketalized ketones. As one approach, the ketone is reacted with a halogen donor compound, e.g., N-chlorosuccinimide, in anhydrous, ...  
WO/2007/039110A2
The invention relates to compounds according to formula (I) or formula (II), wherein R is H or (CHOH)nCH2OH (n= 0, 1 or 2), Sp is -CH-, -CHOH-, -(CH2)n-, -(CH=CH)n-, -(CH=CH-CH2)n,-, -(CH2)n-X-(CH2)o-, -(CH2-X)n-(CH2)o-, -(CH2)n-C(=X)-(C...  
WO/2007/039110A3
The invention relates to compounds according to formula (I) or formula (II), wherein R is H or (CHOH)nCH2OH (n= 0, 1 or 2), Sp is -CH-, -CHOH-, -(CH2)n-, -(CH=CH)n-, -(CH=CH-CH2)n,-, -(CH2)n-X-(CH2)o-, -(CH2-X)n-(CH2)o-, -(CH2)n-C(=X)-(C...  
WO2006129036B1
The invention concerns novel 1,2-dioxetane derivatives of general formula (I) as defined in the description, capable of emitting a detectable luminescent signal, their use in a method for detecting and/or quantizing a physical, chemical ...  
WO/2007/034909A1
Disclosed is a (3R,5R)-7-amino-3,5-dihydroxyheptanoic acid derivative which is useful as an intermediate for a pharmaceutical. A (3R,5R)-7-amino-3,5-dihydroxyheptanoic acid derivative or a salt thereof can be produced by a process compri...  
WO/2007/032362A1
It is intended to provide a substituted cycloalkene derivative represented by the general formula (I) which has an action of suppressing intracellular signal transduction or cell activation caused by endotoxin and a cell response such as...  
WO/2007/027599A1
This invention provides compounds of Formula (I) having the structure where R1, R2, R3 and A are defined in the specification or a pharmaceutically acceptable salt thereof useful as antibacterial agents. Compounds according to Formula (I...  
WO/2007/015412A1
Disclosed is an organic electroluminescent device (organic EL device) of simple structure which is improved in luminous efficiency and sufficiently secured in driving stability. Also disclosed is a heterocyclic compound used for such an ...  
WO/2007/013201A1
A zinc fluorescent probe that excels in water solubility, enabling observing with high sensitivity of any change of intracellular zinc ion level ratiometrically with the use of a single excited wavelength; a process for producing the sam...  
WO/2007/010514A2
Therefore the present invention relates specifically to the compounds of general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising H, -CnH2n-1, a linear or branched alkyl group h...  
WO/2007/010514A3
Therefore the present invention relates specifically to the compounds of general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising H, -CnH2n-1, a linear or branched alkyl group h...  
WO2005105776A8
Compounds of the formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein m, n, p, Ar, X, R1, R2, R3, R4, R5 and R6 are as defined herein as well as compositions comprising these compounds and uses of the s...  
WO/2007/000383A1
Biphenyl and phenyl-naphthyl compounds bearing a hydroxamic group, which are endowed with antitumour, and anti-angiogenic activity These compounds are therefore particularly useful for the treatment of drug-resistant tumours.  
WO2006020358A3
The invention is directed to certain biphenyl compounds. Specifically, the invention is directed to compounds according to Formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and Y are as defined below, and to pharmaceutically-accep...  
WO2006058648A3
The present invention relates to compounds of Formula (I) wherein Ar, Ar2,R2, R3, R4, m, p and s are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/...  
WO/2006/134955A1
A compound represented by the general formula (1) or (100), a salt thereof or a hydrate of the compound or salt, which is excellent in cell adhesion-inhibitory effect and cell infiltration-inhibitory effect: (1) (100) wherein R10 represe...  
WO2005108479A3
An acetal-based composition useful as a nucleating, gelling, thickening or clarifying agent is disclosed. The composition may be synthesized or provided in many different forms, including multicarbon diacetals formed from carbohydrates. ...  
WO/2006/129036A3
The invention concerns novel 1,2-dioxetane derivatives of general formula (I) as defined in the description, capable of emitting a detectable luminescent signal, their use in a method for detecting and/or quantizing a physical, chemical ...  
WO/2006/129736A1
It is intended to provide an industrially advantageous process for producing a cyclic ester, an industrially advantageous process for producing a cyclic oxyester which is a raw material of poly(hydroxyalkyloxyacetic acid ester), and an i...  
WO/2006/129036A2
The invention concerns novel 1,2-dioxetane derivatives of general formula (I) as defined in the description, capable of emitting a detectable luminescent signal, their use in a method for detecting and/or quantizing a physical, chemical ...  
WO/2006/127235A3
Clarified polyolefins such as polypropylene are used widely to make polymer articles, containers, and the like. Such articles may be manufactured by the injection of molten polymer into a mold or forming device in manufacturing processes...  
WO/2006/123726A1
A pharmaceutical composition comprising (a) a phosphodiesterase (PDE)-IV inhibitor or a pharmacologically acceptable salt thereof and (b) vitamin D or a vitamin D derivative or a pharmacologically acceptable salt thereof; a therapeutic a...  
WO/2006/124899A3
There are disclosed methods for producing derivatives of lactide, including lactamides, propylene glycol, esters, acid anhydrides, modified starches, acrylic acid and pyruvic acid. Also disclosed are methods for producing lactide. Use of...  
WO/2006/124899A2
There are disclosed methods for producing derivatives of lactide, including lactamides, propylene glycol, esters, acid anhydrides, modified starches, acrylic acid and pyruvic acid. Also disclosed are methods for producing lactide. Use of...  
WO2006061372A3
The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and affinity for dopamine -D2 receptors and to methods for the preparation of these compounds. The invention...  
WO/2006/121095A1
A pharmaceutical composition comprising a compound having the general formula (I) or a pharmacologically acceptable salt thereof as the active ingredient: (I) wherein R1 represents a C6-C10 aryl group which may be substituted by a residu...  
WO/2006/120755A1
Provided is a process for producing a cyclic acetal form of 3-oxocyclopentane-1-carboxylic acid more efficiently and industrially advantageously. The process for producing a cyclic acetal form of 3-oxocyclopentane-1-carboxylic acid repre...  

Matches 351 - 400 out of 6,958